Health ❯ Healthcare ❯ Pharmaceuticals

Drug Regulation

FDA FDA Actions FDA Decisions Mifepristone Counterfeit Drugs GLP-1 Drugs FDA Leadership Counterfeit Medications Compounding Pharmacies FDA Oversight

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

The move signals the agency sees no clinical need for bulk versions given improved supply.

Telangana Regulator Warns Against Unsupervised Semaglutide Use

India Tightens Oversight as Low‑Cost Semaglutide Hits Pharmacies

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

India Warns Drugmakers Over Indirect Promotion of GLP‑1 Weight‑Loss Drugs

UK Orders Class 2 Recall of Ramipril Batch After Amlodipine Found in Packs

FDA Biologics Chief Vinay Prasad to Step Down at End of April

Delhi Crackdown on Cancer Medicines Flags 6 Firms for Violations

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Peru Orders Recall and Destruction of Sulfato Ferroso 300 mg Lot 2077104 After Quality Failure

Brazil Bans Unregistered Tirzepatide Brands and Retatrutide as Seizures Mount

CDSCO Flags 167 Drug Samples as Not of Standard Quality in December

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Telangana Orders Stop-Use of Almont-Kid Syrup After Ethylene Glycol Found

UK Regulator Orders Stronger Addiction Warnings on Benzodiazepines, Gabapentinoids and Z‑Drugs

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

Gilead Starts Shipping Twice-Yearly HIV Prevention Shot to Eswatini and Zambia

France’s Drug Regulator Orders Halt to ‘GLP‑1’ Patch Sales on Seven Websites